Pipeline Review for Heavy Metal Poisoning – H1 2020 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Heavy Metal Poisoning – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This latest report provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.

Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and diarrhea. Treatment includes chelation therapy.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Heavy Metal Poisoning – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 2, 1 and 4 respectively. Similarly, the Universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. (Read more…) Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology).
• The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Heavy Metal Poisoning – Overview
• Heavy Metal Poisoning – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Heavy Metal Poisoning – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Heavy Metal Poisoning – Companies Involved in Therapeutics Development
• Heavy Metal Poisoning – Drug Profiles
• Heavy Metal Poisoning – Dormant Projects
• Heavy Metal Poisoning – Discontinued Products
• Heavy Metal Poisoning – Product Development Milestones
• Featured News & Press Releases
• Sep 21, 2018: President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) symposium
• Sep 21, 2018: President presents at the 2018 International Academy of Oral Medicine and Toxicology (IAOMT) symposium
• Mar 30, 2017: SRI International Receives U.S. FDA Clearance for Investigating New Drug Application Evaluating Novel Oral Treatment to Combat Radiation Exposure
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer

Companies Mentioned

• Capture Pharmaceuticals Inc
• DisperSol Technologies LLC
• EmeraMed Ltd
• Medesis Pharma SA
• PDX Pharmaceuticals LLC
• ZoneOne Pharma Inc

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/fzftsd

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900